ATLANTA, September 9 /PRNewswire/ --

Celonova Biosciences, Inc. ("CeloNova"), a leading developer of
innovative medical devices, today announced that the paper, "Comparison of
late in-stent stenosis and vessel wall inflammation in Cypher(R) Select(TM),
Taxus(R) Express(TM), and Polyzene(R)-F nanocoated cobalt chromium stents in
a porcine coronary artery model" prepared by Dr. Boris Radeleff has been
chosen to receive the CIRSE 2007 Magna Cum Laude EPOS Award.

"We are delighted that Dr. Radeleff has been honored by his peers for his
work comparing the performance of the leading drug-eluting stents to a stent
treated with CeloNova's proprietary Polyzene(R)-F medically inert surface
coating," said Thomas A. Gordy, CeloNova President and Chief Executive
Officer. "This award validates the high quality of the work undertaken by Dr.
Radeleff and his colleagues to understand how Polyzene(R)-F can enhance the
performance of coronary stents by inhibiting restenosis and thrombus
formation without the need to resort to an anti-proliferative drug or
long-term dual antiplatelet medications. We continue to believe, based on
this and other ongoing research, that Polyzene(R)-F represents a
revolutionary breakthrough in the quest to develop the ideal long-term
solution for coronary stenting."

Dr. Radeleff, a physician at the University Hospital of Heidelberg,
received his award at the CIRSE Opening Ceremony and Awards Session in
Athens, Greece on Saturday, September 08.

About CIRSE

The Cardiovascular and Interventional Radiological Society of Europe is a
non-profit making, educational and scientific association of 2,300
interventional professionals with an active personal involvement and interest
in interventional radiology or cardiovascular imaging techniques.

About CIRSE 2007

The CIRSE Annual Scientific and Postgraduate Educational Meeting has
established itself as the premier gathering for all professionals devoted to
the field of Cardiovascular and Interventional Radiology in Europe. CIRSE
2007 is a unique forum where medical professionals can meet their colleagues
from all around the world, and exchange ideas and information in the field of
minimally invasive, image guided therapies.

About CeloNova BioSciences, Inc.

Headquartered near Atlanta, Georgia, CeloNova BioSciences, Inc., is a
developer of novel medical devices based on the company's patented
Polyzene(R)-F surface coating technology. Polyzene(R)-F is highly lubricious,
and possesses both anti-bacterial and anti-inflammatory properties that make
it an ideal surface treatment for implanted medical devices. The company's
current product portfolio includes its Embozene(TM) Microspheres, used to
treat arteriovenous malformations, hypervascularized tumors, uterine fibroids
and hepatocellular carcinoma. Other innovative devices are currently in the
company's developmental pipeline. For more information, please visit
www.celonova.com.

Contact: Thomas A. Gordy
    President and Chief Executive Officer
    +1-770-502-0304



Web site: http://www.celonova.com